Results 21 to 30 of about 21,523 (174)

The influence of residual apixaban on bleeding complications during and after catheter ablation of atrial fibrillation

Journal of Arrhythmia, 2017
Background: The periprocedural protocol for atrial fibrillation (AF) ablation commonly includes anticoagulation therapy. Apixaban, a direct oral anticoagulant, is currently approved for clinical use; however, little is known about the effects of residual
Yutaro Mukai, Kyoichi Wada, Koji Miyamoto, Kazuki Nakagita, Mai Fujimoto, Kouichi Hosomi, Takeshi Kuwahara, Mitsutaka Takada, Kengo Kusano, Akira Oita   +9 more
doaj   +1 more source

Carbamazepine Induction Impacting Apixaban Concentrations: A Case ReportNovel Teaching Points

CJC Open, 2020
Avoidance of apixaban with carbamazepine (CBZ) is recommended owing to an anticipated reduction in apixaban concentration, although this drug interaction is poorly described. We report a case wherein apixaban concentration was measured before and 2 weeks
Tammy J. Bungard, BSP, PharmD, R. Neil Roberts, MD   +1 more
doaj   +1 more source

Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder

CPT: Pharmacometrics & Systems Pharmacology, 2023
Apixaban is an oral small‐molecule, direct factor Xa (FXa) inhibitor approved in adults for treatment of deep vein thrombosis and pulmonary embolism, and for reducing risk of venous thromboembolism recurrence after initial anticoagulant therapy.
Samira J. Merali, Wonkyung Byon, Yogesh T. Patel, Amira Elsrougy, David Marchisin, Vidya Perera, Weidong Chen, Bing He, Bindu Murthy   +8 more
doaj   +1 more source

Guía de práctica clínica para la prevención, diagnóstico y tratamiento de la enfermedad tromboembólica venosa en el deporte [PDF]

, 2015
  El término enfermedad tromboembólica venosa se refiere a varios procesos patológicos, entre los que destacan la trombosis venosa profunda, el tromboembolismo pulmonar, la hipertensión pulmonar tromboembólica crónica y el síndrome postrombótico.
Drobnic, Franchek, Pineda, Antoni, Román Escudero, José, Soria, José Manuel, Souto, Joan Carles   +4 more
core   +1 more source

Does amiodarone impact on apixaban levels? The effect of amiodarone on apixaban level among Thai patients with non-valvular Atrial Fibrillation.

PLoS ONE
BackgroundApixaban and amiodarone are drugs used for non-valvular atrial fibrillation (NVAF) in routine practice. The evidence about apixaban plasma levels in patients who receive apixaban with amiodarone, including bleeding outcomes, has been limited ...
Sutee Limcharoen, Sarawuth Limprasert, Pornwalai Boonmuang, Manat Pongchaidecha, Juthathip Suphanklang, Weerayuth Saelim, Wichai Santimaleeworagun, Piyarat Pimsi   +7 more
doaj   +1 more source

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban

Frontiers in Pharmacology, 2023
Background: Almonertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is commonly used as a first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutations.
Zhi Wang, Ying Li, Xueru He, Yuhao Fu, Yajing Li, Xin Zhou, Zhanjun Dong   +6 more
doaj   +1 more source

Uso de los nuevos anticoagulantes orales en el síndrome antifosfolipidico: revisión bibliográfica [PDF]

, 2023
Antecedentes. El síndrome antifosfolipídico es considerado a nivel mundial la trombofilia adquirida más abundante, con una prevalencia de 40 a 50 casos por cada 100.000 habitantes en general, con mayor predisposición en mujeres, con una relación 5:1 en ...
Caraguay, Sarahí Alejandra Vergara, Di Rosa, Rebeca Rodríguez, Espinoza, Esteban Adrián Reibán, Iñiguez, Mateo Nicolás Andrade, Lanzarin, Ana Lara Braga, Ortiz, Kevin Sebastian Criollo, Sanmartín, Fausto Andrés Martínez, Vivar, María Angélica Córdova   +7 more
core   +1 more source

Conventional and synchronous spectrofluorometric determination of the recently administered drugs for treatment of COVID-19 favipiravir and apixaban

Scientific Reports, 2022
COVID-19 is a fast-spreading pandemic that is caused by SARS-CoV-2 viral pathogen. Combination therapy of the antiviral favipiravir and the anticoagulant apixaban is one of the efficient treatment regimens.
Heba Samir Elama, Abdallah M. Zeid, Shereen M. Shalan, Yasser El-Shabrawy, Manal I. Eid   +4 more
doaj   +1 more source

Situación actual de los nuevos anticoagulantes orales [PDF]

, 2013
For more than half a century, vitamin K antagonists have defined oral anticoagulant therapy for the long-term management of thrombotic disorders. Despite its clinical efficacy, vitamin-antagonists have multiple, well-known limitations, including numerous
Albarrán Severo, Beatriz, Andujar Troncoso, Giselle, Cidoncha Morcillo, Borja, García Frade, Luis Javier, González Mena, Beatriz   +4 more
core   +1 more source

Differential Risk of Intracranial Hemorrhage in Patients with Non-valvular Atrial Fibrillation with Usage of Novel Oral Anticoagulantsvs. Warfarin. Systematic Review and Analysis of Subpopulations [PDF]

, 2017
Introducción: La anticoagulación en pacientes con fibrilación auricularno valvular previene eventos tromboembólicos con incremento implícitoen el riesgo de complicaciones hemorrágicas, principalmente lahemorragia intracraneana. Métodos: Se realizó
Aruachán Torres, Samir Alejandro, Ayala Copete, Ana María, Cano Gutiérrez, Camilo Alberto, García Peña, Ángel Alberto, Patiño Hernandez, Daniela, Pontificia Universidad Javeriana. Facultad de Medicina. Instituto de Envejecimiento, Ríos Zuluaga, Julian David   +6 more
core   +1 more source